Lucid Diagnostics (NASDAQ:LUCD) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD - Free Report) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $2.00 price target on the stock.

A number of other analysts have also weighed in on LUCD. Needham & Company LLC upped their price objective on Lucid Diagnostics from $2.50 to $3.00 and gave the stock a "buy" rating in a research report on Monday, March 24th. Ascendiant Capital Markets reduced their price target on Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating on the stock in a research report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $3.40.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD traded down $0.01 during midday trading on Wednesday, hitting $1.58. The company's stock had a trading volume of 701,358 shares, compared to its average volume of 362,517. Lucid Diagnostics has a 1 year low of $0.63 and a 1 year high of $1.63. The business's fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $1.01. The firm has a market capitalization of $93.76 million, a price-to-earnings ratio of -1.39 and a beta of 1.34.

Remove Ads

Hedge Funds Weigh In On Lucid Diagnostics

Large investors have recently bought and sold shares of the business. Sargent Investment Group LLC acquired a new position in shares of Lucid Diagnostics during the 4th quarter worth about $442,000. LPL Financial LLC boosted its holdings in Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock valued at $44,000 after purchasing an additional 12,035 shares in the last quarter. Geode Capital Management LLC increased its stake in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock valued at $229,000 after purchasing an additional 65,964 shares during the last quarter. Lido Advisors LLC raised its holdings in Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 4th quarter valued at $98,000. Hedge funds and other institutional investors own 74.01% of the company's stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.